Sefam Medical Ltd

Sefam UK is launching the innovative Nea CPAP/APAP device. Head to our website to check out Nea’s unique features and first of its kind technology sound abatement system. https://lnkd.in/eFMuDF4v Sefam SEFAM INDIA Sefam Medical South Europe #safety #silence #innovation #osa #cpaptherapy #honeycomb

https://lnkd.in/eVYRngU6 People with OSA who discontinue CPAP therapy face a substantially higher risk of serious cardiovascular problems and death. This elevated risk persists even when considering other contributing factors. Although the study didn't show a connection to heart failure or coronary artery disease, it did reveal lower rates of adherence to cardiovascular medications among those who stopped using CPAP. More research is necessary to develop strategies for improving PAP therapy adherence. Congratulations to all the author’s AbdelKebir SABIL, PhD Claire Launois et al Sébastien BAILLY Pr Frédéric Gagnadoux

Sefam UK is launching the Nea CPAP/APAP device. Visit our website to find out more on our innovative technology to treat Sleep Apnoea. sefam-uk.co.uk Michael McEwan Katie Simpson Anthony W. Allen Kuldip Madar Liam Ions Callum Gilkes Charlotte Gough Sefam SEFAM INDIA Sefam Medical South Europe Sefam Medical Ltd

This is the first in a series of 5 blogs from Sefam UK on differentiating between OSA and CSA - and the most recent published evidence on this. Any feedback is appreciated. We will post the successive blogs each week. https://lnkd.in/eznVyRfM Sefam Medical Ltd Sefam SEFAM INDIA Sefam Medical South Europe Michael McEwan Katie Simpson Kuldip Madar Anthony W. Allen Liam Ions Callum Gilkes Charlotte Gough AbdelKebir SABIL, PhD Hugo Haan

Early view in ERJ - recommended read here ⬇ This study explored the frequency, types, and impact of side effects from masks used in home non-invasive ventilation (NIV) for those with chronic respiratory failure. It involved 800 stable patients already using long-term NIV, with 84% of them using oronasal masks. Results showed that 47% experienced moderate to very severe side effects, and 18% had severe to very severe side effects, linked to worse daytime PaCO2 levels, poorer sleep quality, and lower quality of life. Oronasal masks were associated with more frequent side effects than nasal masks. A bench study also showed nasal masks were more stable. The findings suggest that nasal masks may be more tolerable and could be considered as the preferred initial choice for NIV interfaces. This has been my experience in clinical practice for many years, Congratulations to all the authors. Emeline Fresnel Christian Caillard Marius LEBRET Léa Razakamanantsoa @Adrien Kerfourn Johan Dupuis Jean Francois MUIR Rue Verte R@Elodie Lhuillier Kinan El Husseini@thomas Similowski Antoine CUVELIER Maxime Patout Sefam Medical Ltd Sefam SEFAM INDIA Sefam Medical South Europe https://lnkd.in/e63AnqYc

Sefam are celebrating 40 years of innovation with the launch of the Nea in the UK and global markets. Sefam has a presence in over 60 counties with a proven track record of reliability. The Nea is the fist CPAP/ APAP device that does not use noise cancelling foam and is one of the quietist devices on the market. Nea also boasts an advanced algorithm, connectivity features, cloud-enabled management system, and a patient-interactive app that enhances the therapy experience. Our commitment to safety and reliability is what sets us apart, and the Nea is no exception. More information on the Nea can be found on our website here ⬇️ www.sefam-uk.co.uk/ #CPAPinnovation #Néalveole®technology Michael McEwan Katie Simpson Kuldip Madar Anthony W. Allen Liam Ions Callum Gilkes Charlotte Gough AbdelKebir SABIL, PhD Hugo Haan

I am thrilled to announce the UK launch of Sefam's latest CPAP device, the Nea! This innovative device is the first, and only, sound foam-free CPAP machine on the market. After the recent industry scandal caused by devices containing sound abatement foam that in some cases degraded and potentially endangered patients' health, Nea marks a major step forward in restoring confidence in CPAP therapy. It also offers peace of mind to healthcare providers, whose services were impacted by this. Nea has been in development for the past six years. It features a patented “Néalveole® technology” honeycomb structure that provides the necessary sound dampening for a sleep-enhancing device, without the risks associated with sound abatement foam. In my, almost, 20 years leading commercial teams in CPAP design, development, and sales, I’ve rarely seen innovation of this magnitude in both the device’s structure and its array of features. I invite you to visit our website  www.sefam-uk.co.uk and explore the Nea in detail. It boasts an advanced algorithm, connectivity features, cloud-enabled management system, and a patient-interactive app that enhances the therapy experience. Sefam is not new to the market. we’ve been at the forefront of CPAP technology with proven reliability, for over 40 years. Our commitment to safety and reliability is what sets us apart, and the Nea is no exception. We even have a transparent Nea allowing you to see firsthand what makes this device such an extraordinary breakthrough. We will also be hosting webinars to dive into the design and operation, please look out for social media announcements. These sessions are open to all interested parties. The first webinar will focus on the rationale and innovation behind the Nea’s sound foam-free structure and how this sets it apart from anything else on the market. Nea has already been selected in a competitive tender as the CPAP of choice in one of the country’s biggest sleep services. We are confident that the Nea, and its management software, will be a credible alternative or valuable addition to your current CPAP system, depending on which devices you currently use. The evidence of the last three years shows that having a second supplier to reduce the risk of losing your CPAP supply, would help mitigate the risks of not being able to deliver your service if another recall were to happen. Nea is now live in the NHS supply chain catalogue. I welcome you to the future of CPAP design, and I look forward to your questions. Mike McEwan MD Sefam Medical Ltd www.sefam-uk.co.uk Sefam Sefam Medical Ltd Sefam Medical South Europe SEFAM INDIA ARTP British Sleep Society British Thoracic Society (BTS) British Society of Pharmacy Sleep Services (BSPSS) Michael McEwan Phyllis Murphie RN, PhD Katie Simpson Anthony W. Allen Kuldip Madar Charlotte Gough Liam Ions Callum Gilkes #Nea #CPAPinnovation #soundfreefoam #honeycomb #Néalveole®technology

This systematic review analysed the economic cost of OSA. Annual costs per patient varied widely (€236–€28,267), influenced by study methodology and population characteristics. Direct healthcare costs were consistently reported, but indirect costs (lost productivity, etc.) and direct non-healthcare costs were less consistently measured. Costs increased significantly after diagnosis but remained elevated years prior. OSA severity and CPAP adherence had inconsistent effects on cost. Comorbidities significantly increased costs. The substantial economic burden of OSA highlights the need for earlier diagnosis and effective treatment. Sefam Medical Ltd Sefam SEFAM INDIA Sefam Medical South Europe Michael McEwan Katie Simpson Kuldip Madar Anthony W. Allen AbdelKebir SABIL, PhD #osa #earlydiagnosis #earlytreatment

This study shows that people adhering to CPAP therapy for OSA exhibit healthier behaviors (e.g., better cardiovascular medication adherence, non-smoking) and lower healthcare resource use before commencing CPAP treatment. Adherence to CPAP was linked to these healthy behaviors. However, the study cautions that the "healthy adherer effect" needs further investigation before causal links can be established between CPAP adherence and improved health outcomes. Another interesting study here in Chest ⬇️ Congrats to the authors @Claire Launois Sébastien BAILLY AbdelKebir SABIL, PhD @François Goupil @Thierry Pigeanne @Carole Hervé @Philippe Masson @Acya Bizieux-Thaminy @Nicole Meslier Sandrine KERBRAT @Wojciech Trzepizur Pr Frédéric Gagnadoux Sefam Medical Ltd Sefam Sefam Medical South Europe SEFAM INDIA

Not distinguishing between central and obstructive hypopneas may lead to an underestimation of CSA severity, adversely affecting treatment decisions and limiting potential improvements in quality of life and sleepiness for appropriately treated patients with CSA. Important finding in this research here ⬇ Sefam Medical Ltd Sefam Sefam Medical South Europe SEFAM INDIA Michael McEwan Katie Simpson Kuldip Madar Anthony W. Allen Charlotte Gough AbdelKebir SABIL, Congratulations to all the authors Jean-louis pepin, Alan Schwartz Rami Khayat robin germany Scott McKane van Ngo Sébastien BAILLIEUL Sébastien BAILLY Renaud Tamisier Link to full paper also in comments